Acute promyelocytic leukemia

For other uses, see APL (disambiguation).
Acute promyelocytic leukemia

Classification and external resources
Specialty Hematology and oncology
ICD-10 C92.4
ICD-9-CM 205.0
ICD-O M9866/3
OMIM 102578
DiseasesDB 34779
eMedicine med/34
MeSH D015473

Acute promyelocytic leukemia (APML, APL) is the M3 subtype of acute myelogenous leukemia (AML), a cancer of the white blood cells.[1] In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes. The disease is characterized by a chromosomal translocation involving the retinoic acid receptor alpha (RARα or RARA) gene and is distinguished from other forms of AML by its responsiveness to all-trans retinoic acid (ATRA; also known as tretinoin) therapy. Acute promyelocytic leukemia was first characterized in 1957[2][3] by French and Norwegian physicians as a hyperacute fatal illness,[1] with a median survival time of less than a week.[4] Today, prognoses have drastically improved; 10-year survival rates are estimated to be approximately 77% according to one study.[5][4]

Signs and symptoms

The symptoms tend to be similar to AML in general with the following being possible symptoms:[6]

Easy bleeding from low platelets may include:

Pathogenesis

Acute promyelocytic leukemia is characterized by a chromosomal translocation involving the retinoic acid receptor-alpha gene on chromosome 17 (RARA).[1] In 95% of cases of APL, retinoic acid receptor-alpha (RARA) gene on chromosome 17 is involved in a reciprocal translocation with the promyelocytic leukemia gene (PML) on chromosome 15, a translocation denoted as t(15;17)(q22;q12).[1] The RAR receptor is dependent on retinoic acid for regulation of transcription.[1]

Eight other rare gene rearrangements have been described in APL fusing RARA to promyelocytic leukemia zinc finger (PLZF also known as ZBTB16),[7] nucleophosmin(NPM1), nuclear matrix associated (NUMA1), signal transducer and activator of transcription 5b (STAT5B), protein kinase A regulatory subunit 1α (PRKAR1A), factor interacting with PAPOLA and CPSF1 (FIP1L1), BCL6 corepressor (BCOR) or oligonucleotide/oligosaccharide-binding fold containing 2A (OBFC2A also known as NABP1) genes. Some of these rearrangements are ATRA-sensitive or have unknown sensitivity to ATRA because they are so rare; STAT5B/RARA and PLZF/RARA are known to be resistant to ATRA.[1]

The fusion of PML and RARA results in expression of a hybrid protein with altered functions. This fusion protein binds with enhanced affinity to sites on the cell's DNA, blocking transcription and differentiation of granulocytes. It does so by enhancing interaction of nuclear co-repressor (NCOR) molecule and histone deacetylase (HDAC). Although the chromosomal translocation involvingRARA is believed to be the initiating event, additional mutations are required for the development of leukemia.[1]

RAR-α/PLZF gene fusion produces a subtype of APL that is unresponsive to tretinoin therapy and less responsive to standard anthracycline chemotherapy hence leading to poorer long-term outcomes in this subset of patients.[1]

Diagnosis

Acute promyelocytic leukemia can be distinguished from other types of AML based on morphologic examination of a bone marrow aspirate or biopsy as well as finding the characteristic rearrangement. Definitive diagnosis requires testing for the PML/RARA fusion gene. This may be done by polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), or conventional cytogenetics of peripheral blood or bone marrow. This mutation involves a translocation of the long arm chromosomes of 15 and 17. On rare occasions, a cryptic translocation may occur which cannot be detected by cytogenetic testing; on these occasions PCR testing is essential to confirm the diagnosis.[1] Presence of multiple Auer rods on peripheral blood smear is highly suggestive of acute promyelocytic leukemia.

Treatment

Initial treatment

Tretinoin
Mitozantrone
Methotrexate

APL is unique among leukemias due to its sensitivity to all-trans retinoic acid (ATRA; tretinoin), the acid form of vitamin A.[1] Treatment with ATRA dissociates the NCOR-HDACL complex from RAR and allows DNA transcription and differentiation of the immature leukemic promyelocytes into mature granulocytes by targeting the oncogenic transcription factor and its aberrant action.[1] Unlike other chemotherapies, ATRA does not directly kill the malignant cells.[1] ATRA induces the terminal differentiation of the leukemic promyelocytes, after which these differentiated malignant cells undergo spontaneous apoptosis on their own. ATRA alone is capable of inducing remission but it is short-lived in the absence of concurrent "traditional" chemotherapy.[1] As of 2013 the standard of treatment for concurrent chemotherapy has become Arsenic trioxide,[8] before 2013 the standard of treatment was anthracycline (e.g.daunorubicin, doxorubicin, idarubicin or mitoxantrone)-based chemotherapy. Both chemotherapies result in a clinical remission in approximately 90% of patients with arsenic trioxide having a more favorable side effect profile.[5]

ATRA therapy is associated with the unique side effect of retinoic acid syndrome.[9] This is associated with the development of dyspnea, fever, weight gain, peripheral edema and is treated with dexamethasone.[10] The etiology of retinoic acid syndrome has been attributed to capillary leak syndrome from cytokine release from the differentiating promyelocytes.[10]

The monoclonal antibody, gemtuzumab ozogamicin, has been used successfully as a treatment for APL.,[11] although it has been withdrawn from the US market due to concerns regarding potential toxicity of the drug and it is not currently marketed in Australia, Canada or the UK.[11][12] It given in conjunction with ATRA produces a response in around 84% of patients with APL, which is comparable to the rate seen in patients treated with ATRA and anthracycline-based therapy.[11] It produces less cardiotoxicity than anthracycline-based treatments and hence may be preferable in these patients.[11]

Maintenance therapy

After stable remission is induced, the standard of care is to undergo 2 years of maintenance chemotherapy with methotrexate, mercaptopurine and ATRA.[13] A significant portion of patients will relapse without consolidation therapy.[10] In the 2000 European APL study, the 2-year relapse rate for those that did not receive consolidation chemotherapy (ATRA not included) therapy was 27% compared to 11% in those that did receive consolidation therapy (p<0.01).[14] Likewise in the 2000 US APL study, the survival rates in those receiving ATRA maintenance was 61% compared to just 36% without ATRA maintenance.[15]

Relapsed or refractory disease

Arsenic trioxide (As2O3) is currently being evaluated for treatment of relapsed / refractory disease. Remission with arsenic trioxide has been reported.[16] Studies have shown arsenic reorganizes nuclear bodies and degrades the mutant PML-RAR fusion protein.[17] Arsenic also increases caspase activity which then induces apoptosis.[18] It does reduce the relapse rate for high risk patients.[19] In Japan a synthetic retinoid, tamibarotene, is licensed for use as a treatment for ATRA-resistant APL.[20]

Investigational agents

Some evidence supports the potential therapeutic utility of histone deacetylase inhibitors such as valproic acid or vorinostat in treating APL.[21][22][23] According to one study, a cinnamon extract has effect on the apoptotic process in acute myeloid leukemia HL-60 cells.[24]

Prognosis

Prognosis is generally good relative to other leukemias. Because of the acuteness of onset compared to other leukemias, early death is comparatively more common. The cause of early death is most commonly severe bleeding, often intracranial hemorrhage. Early death from hemorrhage occurs in 5-10% of patients in countries with adequate access to healthcare and 20-30% of patients in less developed countries. Risk factors for early death due to hemorrhage include delayed diagnosis, late treatment initiation, and high white blood cell count on admission. [25] Despite advances in treatment, early death rates have remained relatively constant. [26]

Relapse rates are extremely low. Most deaths following remission are from other causes, such as second malignancies, which in one study occurred in 8% of patients. In this study, second malignancies accounted for 41% of deaths, and heart disease, 29%. Survival rates were 88% at 6.3 years and 82% at 7.9 years.[27]

In another study, 10-year survival rate was estimated to be approximately 77%.[5]

Epidemiology

Acute promyelocytic leukemia represents 10-12% of AML cases.[11] The median age is approximately 30–40 years,[28] which is considerably younger than the other subtypes of AML (70 years). Incidence is higher among individuals of Latin American or South European origin.[29] It can also occur as a secondary malignancy in those that receive treatment with topoisomerase II inhibitors (such as the anthracyclines and etoposide) due to the carcinogenic effects of these agents, with patients with breast cancer representing the majority of such patients.[30][31][32] Around 40% of patients with APL also have a chromosomal abnormality such as trisomy 8 or isochromosome 17 which do not appear to impact on long-term outcomes.[1]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Kotiah, SD; Besa, EC (3 June 2013). Sarkodee-Adoo, C; Talavera, F; Sacher, RA; McKenna, R; Besa, EC, eds. "Acute Promyelocytic Leukemia". Medscape Reference. WebMD. Retrieved 14 January 2014.
  2. ↑ Tallman MS, Altman JK (2008). "Curative strategies in acute promyelocytic leukemia". Hematology Am Soc Hematol Educ Program. 2008: 391–9. doi:10.1182/asheducation-2008.1.391. PMID 19074116.
  3. ↑ Hillestad, LK (November 1957). "Acute promyelocytic leukemia". Acta Med Scand. 159 (3): 189–94. doi:10.1111/j.0954-6820.1957.tb00124.x. PMID 13508085.
  4. 1 2 Coombs, C. C.; Tavakkoli, M.; Tallman, M. S. (2015-04-17). "Acute promyelocytic leukemia: where did we start, where are we now, and the future". Blood Cancer Journal. 5 (4): e304. doi:10.1038/bcj.2015.25. PMC 4450325Freely accessible. PMID 25885425.
  5. 1 2 3 Adès, L; Guerci, A; Raffoux, E; Sanz, M; Chevallier, P; Lapusan, S; Recher, C; Thomas, X; Rayon, C; Castaigne, S; Tournilhac, O; de Botton, S; Ifrah, N; Cahn JY; Solary E; Gardin, C; Fegeux, N; Bordessoule, D; Ferrant, A; Meyer-Monard, S; Vey, N; Dombret, H; Degos, L; Chevret, S; Fenaux, P; European APL Group (March 2010). "Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience" (PDF). Blood. 115 (9): 1690–1696. doi:10.1182/blood-2009-07-233387. PMID 20018913.
  6. ↑ Kotiah, SD; Besa, EC (3 June 2013). Sarkodee-Adoo, C; Talavera, F; Sacher, RA; McKenna, R; Besa, EC, eds. "Acute Promyelocytic Leukemia Clinical Presentation". Medscape Reference. WebMD. Retrieved 14 January 2014.
  7. ↑ Chen Z, Brand NJ, et al. (March 1993). "Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia". EMBO J. 12 (3): 1161–7. PMC 413318Freely accessible. PMID 8384553.
  8. ↑ Francesco Lo-Coco, M.D.; et al. (July 2013). "Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia". New England Journal of Medicine. 369 (2): 111–121. doi:10.1056/NEJMoa1300874. PMID 23841729.
  9. ↑ Breccia, M; Latagliata, R; Carmosino, I; Cannella, L; Diverio, D; Guarini, A; De Propris, MS; Petti, MC; Avvisati, G; Cimino, G; Mandelli, F; Lo-Coco, F (December 2008). "Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin". Haematologica. 93 (12): 1918–20. doi:10.3324/haematol.13510. PMID 18945746.
  10. 1 2 3 Kotiah, SD; Besa, EC (3 June 2013). Sarkodee-Adoo, C; Talavera, F; Sacher, RA; McKenna, R; Besa, EC, eds. "Acute Promyelocytic Leukemia Treatment & Management". Medscape Reference. WebMD. Retrieved 14 January 2014.
  11. 1 2 3 4 5 Ravandi, F; Estey, EH; Appelbaum, FR; Lo-Coco, F; Schiffer, CA; Larson, RA; Burnett, AK; Kantarjian, HM (November 2012). "Gemtuzumab Ozogamicin: Time to Resurrect?" (PDF). Journal of Clinical Oncology. 30 (32): 3921–3923. doi:10.1200/JCO.2012.43.0132. PMID 22987091.
  12. ↑ Martindale: The Complete Drug Reference. Pharmaceutical Press. 23 September 2011.
  13. ↑ Kotiah, SD (28 October 2013). Anand, J; Braden, CD; Harris, JE, eds. "Acute Promyelocytic Leukema Treatment Protocols". Medscape Reference. WebMD. Retrieved 14 January 2014.
  14. ↑ Fenaux, P; Chastang, C; Chevret, S; Sanz, M; Dombret, H; Archimbaud, E; Fey, M; Rayon, C; Huguet, F; Sotto, JJ; Gardin, C; Makhoul, PC; Travade, P; Solary, E; Fegueux, N; Bordessoule, D; Miguel, JS; Link, H; Desablens, B; Stamatoullas, A; Deconinck, E; Maloisel, F; Castaigne, S; Preudhomme, C; Degos, L (August 1999). "A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia" (PDF). Blood. 94 (4): 1192–1200. PMID 10438706.
  15. ↑ Tallman, MS; Andersen, JW; Schiffer, CA; Appelbaum, FR; Feusner, JH; Woods, WG; Ogden, A; Weinstein, H; Shepherd, L; Willman, C; Bloomfield, CD; Rowe, JM; Wiernik, PH (December 2002). "All-transretinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol" (PDF). Blood. 100 (13): 4298–4302. doi:10.1182/blood-2002-02-0632. PMID 12393590.
  16. ↑ Soignet SL, Maslak P, Wang ZG, et al. (November 1998). "Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide". N. Engl. J. Med. 339 (19): 1341–8. doi:10.1056/NEJM199811053391901. PMID 9801394.
  17. ↑ Soignet,Complete Remission After Treatment of APL with Arsenic Trioxide 1998, 1346
  18. ↑ Soignet, 1998, 1347
  19. ↑ Arsenic Compound Improves Survival in Acute Promyelocytic Leukemia Patients . Sept 2007
  20. ↑ Miwako, I; Kagechika, H (August 2007). "Tamibarotene". Drugs Today (Barc). 43 (8): 563–568. doi:10.1358/dot.2007.43.8.1072615. PMID 17925887.
  21. ↑ Martens, JH; Brinkman, AB; Simmer, F; Francoijs, KJ; Nebbioso, A; Ferrara, F; Altucci, L; Stunnenberg, HG (February 2010). "PML-RARa/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia" (PDF). Cancer Cell. 17 (2): 173–185. doi:10.1016/j.ccr.2009.12.042. PMID 20159609.
  22. ↑ Leiva, M; Moretti, S; Soilihi, H; Pallavicini, I; Peres, L; Mercurio, C; Dal Zuffo, R; Minucci, S; de Thé, H (July 2012). "Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL". Leukemia. 26 (7): 1630–1637. doi:10.1038/leu.2012.39. PMID 22333881.
  23. ↑ He LZ; Tolentino T; Grayson P; et al. (November 2001). "Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia" (PDF). Journal of Clinical Investigation. 108 (9): 1321–1330. doi:10.1172/JCI11537. PMC 209432Freely accessible. PMID 11696577.
  24. ↑ Assadollahi V, Parivar K, Roudbari NH, Khalatbary AR, Motamedi M, Ezatpour B, Dashti GR (2013). "The effect of aqueous cinnamon extract on the apoptotic process in acute myeloid leukemia HL-60 cells". Adv Biomed Res. 2: 25. doi:10.4103/2277-9175.108001. PMC 3748636Freely accessible. PMID 23977653.
  25. ↑ Breccia, Massimo; Latagliata, Roberto; Cannella, Laura; Minotti, Clara; Meloni, Giovanna; Lo-Coco, Francesco (2010-05-01). "Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation". Haematologica. 95 (5): 853–854. doi:10.3324/haematol.2009.017962. ISSN 0390-6078. PMC 2864399Freely accessible. PMID 20015875.
  26. ↑ McClellan, James Scott; Kohrt, Holbrook E.; Coutre, Steven; Gotlib, Jason R.; Majeti, Ravindra; Alizadeh, Ash A.; Medeiros, Bruno C. (2012-01-01). "Treatment advances have not improved the early death rate in acute promyelocytic leukemia". Haematologica. 97 (1): 133–136. doi:10.3324/haematol.2011.046490. ISSN 0390-6078. PMC 3248942Freely accessible. PMID 21993679.
  27. ↑ Shetty, Aditya Vittal; Ravandi, Farhad; Alapati, Naga; Borthakur, Gautam; Garcia-Manero, Guillermo; Kadia, Tapan M.; Wierda, William; Estrov, Zeev; Pierce, Sherry (2014-12-06). "Survivorship in APL- Outcomes of Acute Promyelocytic Leukemia (APL) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years". Blood. 124 (21): 954–954. ISSN 0006-4971.
  28. ↑ Schiffer, CA; Stone, RM (2000). "Chapter 124: Acute Myeloid Leukemia in Adults". In Bast, RC; Kufe, DW; Pollock, RE. Holland-Frei Cancer Medicine (5th ed.). Hamilton, ON: BC Decker. Retrieved 15 January 2014.
  29. ↑ Douer, D; Santillana, S; Ramezani, L; Samanez, C; Slovak, ML; Lee, MS; Watkins, K; Williams, T; Vallejos, C (August 2003). "Acute promyelocytic leukaemia in patients originating in Latin America and is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene". British Journal of Haematology. 122 (4): 563–70. doi:10.1046/j.1365-2141.2003.04480.x. PMID 12899711.
  30. ↑ Ravandi, F (April 2011). "Therapy-related acute promyelocytic leukemia" (PDF). Haematologica. 96 (4): 493–495. doi:10.3324/haematol.2011.041970. PMC 3069223Freely accessible. PMID 21454880.
  31. ↑ Elliott, MA; Letendre, L; Tefferi, A; Hogan, WJ; Hook, C; Kaufmann, SH; Pruthi, RK; Pardanani, A; Begna, KH; Ashrani, AA; Wolanskyj, AP; Al-Kali, A; Litzow, MR (March 2012). "Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy". European Journal of Haematology. 88 (3): 237–243. doi:10.1111/j.1600-0609.2011.01727.x. PMID 22023492.
  32. ↑ Rashidi, A; Fisher, SI (2013). "Therapy-related acute promyelocytic leukemia: a systematic review". Medical Oncology. 30 (3): 625. doi:10.1007/s12032-013-0625-5. PMID 23771799.

External links

This article is issued from Wikipedia - version of the 8/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.